News >

Sacituzumab Govitecan TNBC Application Resubmitted to FDA

Gina Columbus
Published: Tuesday, Dec 03, 2019

Behzad Aghazadeh

Behzad Aghazadeh

Immunomedics has resubmitted its biologics license application (BLA) to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (TNBC) who have received ≥2 prior therapies for metastatic disease.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x